Skip to main content
Log in

Overcoming metastatic melanoma with BRAF inhibitors

  • Report on Investigational Drugs
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Melanoma has the capacity to spread via the blood stream to the brain, and has been notoriously resistant to drug therapy. An activating mutation in the gene encoding BRAF is known to be responsible for half of melanomas. This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of melanomas by inhibiting oncogenic BRAF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arkenau, H. T., Kefford, R., and Long, G. V., Targeting BRAF for patients with melanoma. Br. J. Cancer, 104, 392–398 (2011).

    Article  PubMed  CAS  Google Scholar 

  • Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., Burton, E. A., Wong, B., Tsang, G., West, B. L., Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K. Y., Artis, D. R., Schlessinger, J., Su, F., Higgins, B., Iyer, R., D’Andrea, K., Koehler, A., Stumm, M., Lin, P. S., Lee, R. J., Grippo, J., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., Chapman, P. B., Flaherty, K. T., Xu, X., Nathanson, K. L., and Nolop, K., Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467, 596–599 (2010).

    Article  PubMed  CAS  Google Scholar 

  • Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O’Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., and Chapman, P. B., Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med., 363, 809–819 (2010).

    Article  PubMed  CAS  Google Scholar 

  • Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal. M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., and Garraway, L. A., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468, 968–972 (2010).

    Article  PubMed  CAS  Google Scholar 

  • King, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., Kumar, R., Rusnak, D. W., Takle, A. K., Wilson, D. M., Hugger, E., Wang, L., Karreth, F., Lougheed, J. C., Lee, J., Chau, D., Stout, T. J., May, E. W., Rominger, C. M., Schaber, M. D., Luo, L., Lakdawala, A. S., Adams, J. L., Contractor, R. G., Smalley, K. S., Herlyn, M., Morrissey, M. M., Tuveson, D. A., and Huang, P. S., Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res., 66, 11100–11105 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M. K., Attar, N., Sazegar, H., Chodon, T., Nelson, S. F., McArthur, G., Sosman, J. A., Ribas, A., and Lo, R. S., Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature, 468, 973–977 (2010).

    Article  PubMed  CAS  Google Scholar 

  • Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., Sproesser, K., Li, L., Smalley, K. S., Fong, D., Zhu, Y. L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, Y., Luu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S. H., Schlessinger, J., Zhang, K. Y., West, B. L., Powell, B., Habets, G., Zhang, C., Ibrahim, P. N., Hirth, P., Artis, D. R., Herlyn, M., and Bollag, G., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U. S. A., 105, 3041–3046 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F., Schostack, K., Simcox, M. E., Heimbrook, D., Bollag, G., and Su, F., RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res., 70, 5518–5527 (2010).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sungwoo Hong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hong, S., Hong, S. Overcoming metastatic melanoma with BRAF inhibitors. Arch. Pharm. Res. 34, 699–701 (2011). https://doi.org/10.1007/s12272-011-0521-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-0521-5

Keywords

Navigation